Website
News25/Ratings12
News · 26 weeks42+180%
2025-10-262026-04-19
Mix2590d
- Insider8(32%)
- SEC Filings6(24%)
- Other6(24%)
- Earnings3(12%)
- Analyst2(8%)
Latest news
25 items- SECCertara Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Certara, Inc. (0001827090) (Filer)
- PRCertara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to VeristatTransaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to $135 million. The transaction is expected to close during the second quarter of 2026 subject to customary closing conditions. "Certara's strategy is centered on expanding the scale, reach, and impact of our MIDD and Clinical Intelligence solutions," sai
- PRCertara to Report First Quarter 2026 Financial Results on May 11th, 2026RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulat
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)
- INSIDERSEC Form 4 filed by Pedersen Leif E4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Mckemey Adrian4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Corcoran Daniel4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Gallagher John E4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Aspbury Robert4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Anhalt Rona4 - Certara, Inc. (0001827090) (Issuer)
- SECSEC Form DEFA14A filed by Certara Inc.DEFA14A - Certara, Inc. (0001827090) (Filer)
- SECSEC Form DEF 14A filed by Certara Inc.DEF 14A - Certara, Inc. (0001827090) (Filer)
- SECCertara Inc. filed SEC Form 8-K: Leadership Update8-K - Certara, Inc. (0001827090) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)
- ANALYSTCertara downgraded by Barclays with a new price targetBarclays downgraded Certara from Overweight to Equal Weight and set a new price target of $8.00
- PRCertara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminibRADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced its Simcyp® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug application (NDA) for asciminib (Scemblix®). PBPK modeling uses virtual biological systems to predict how drugs are absorbed, distributed, metabolized, and eliminated by the body, and is increasingly being applied in place of certain clinical studies where appropriate. The results published in "Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical P
- INSIDERSEC Form 4 filed by Director Bedi Arjun4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bedi Arjun3 - Certara, Inc. (0001827090) (Issuer)
- ANALYSTCertara downgraded by Craig Hallum with a new price targetCraig Hallum downgraded Certara from Buy to Hold and set a new price target of $10.00
- PRCertara to Participate in Upcoming Investor ConferencesRADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Date and Time: Tuesday, March 3rd, 2026, at 3:10PM ET Leerink Global Healthcare Conference Date and Time: Monday, March 9th, 2026, at 8:00AM ET Barclays 28th Annual Global Healthcare ConferenceDate and Time: Tuesday, March 10th, 2026, at 1:00PM ET Live webcasts for each of the conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 day
- SECSEC Form 10-K filed by Certara Inc.10-K - Certara, Inc. (0001827090) (Filer)
- SECCertara Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Certara, Inc. (0001827090) (Filer)
- PRCertara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 GuidanceFY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its fourth quarter and full fiscal year 2025 financial results. Fourth Quarter Highlights: Appointment of Jon Resnick as Chief Executive Officer and Member of the Board of Directors, effective January 1st, 2026.Revenue was $103.6 million, compared to $100.4 million i
- PRCertara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medic